BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Java A, Edwards A, Rossi A, Pandey R, Gaut J, Delos Santos R, Miller B, Klein C, Brennan D. Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature. Transpl Int. 2015;28:1121-1125. [PMID: 25864519 DOI: 10.1111/tri.12582] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Salvadori M, Tsalouchos A. Therapeutic apheresis in kidney transplantation: An updated review. World J Transplant 2019; 9(6): 103-122 [PMID: 31750088 DOI: 10.5500/wjt.v9.i6.103] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
2 Fayek SA, Allam SR, Martinez E, Pan G, Dao A, Rofaiel G. Atypical Hemolytic Uremic Syndrome After Kidney Transplantation: Lessons Learned From the Good, the Bad, and the Ugly. A Case Series With Literature Review. Transplant Proc 2020;52:146-52. [PMID: 31924403 DOI: 10.1016/j.transproceed.2019.10.015] [Reference Citation Analysis]
3 Krishnappa V, Gupta M, Manu G, Kwatra S, Owusu OT, Raina R. Acute Kidney Injury in Hematopoietic Stem Cell Transplantation: A Review. Int J Nephrol 2016;2016:5163789. [PMID: 27885340 DOI: 10.1155/2016/5163789] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
4 Filippone EJ, McCue PA, Farber JL. Transplant glomerulopathy. Mod Pathol 2018;31:235-52. [PMID: 29027535 DOI: 10.1038/modpathol.2017.123] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
5 Yokose T, Obara H, Shinoda M, Nakano Y, Kitago M, Yagi H, Abe Y, Yamada Y, Matsubara K, Oshima G, Hori S, Ibuki S, Higashi H, Masuda Y, Hayashi M, Mori T, Kawaida M, Fujimura T, Hoshino K, Kameyama K, Kuroda T, Kitagawa Y. Colon perforation due to antigenemia-negative cytomegalovirus gastroenteritis after liver transplantation: A case report and review of literature. World J Gastroenterol 2019; 25(15): 1899-1906 [PMID: 31057303 DOI: 10.3748/wjg.v25.i15.1899] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kozlovskаya NL, Gаlstyan GM, Stepаnyuk VN; City Clinical Hospital named after A. K. Eramishantsev, Peoples’ Friendship University of Russia, National Medical Research Center of Hematology, Primorskaya Regional Clinical Hospital no. 1. DIFFICULTIES IN DIAGNOSTICS OF ATYPICAL HEMOLYTIC UREMIC SYNDROME IN THE INTENSIVE CARE UNIT. VAIR 2019;16:65-76. [DOI: 10.21292/2078-5658-2019-16-4-65-76] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
7 Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J 2017;10:600-24. [PMID: 28980670 DOI: 10.1093/ckj/sfx081] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
8 Ávila A, Gavela E, Sancho A. Thrombotic Microangiopathy After Kidney Transplantation: An Underdiagnosed and Potentially Reversible Entity. Front Med (Lausanne) 2021;8:642864. [PMID: 33898482 DOI: 10.3389/fmed.2021.642864] [Reference Citation Analysis]
9 Ye Y, Zheng W, Wang J, Hu Y, Luo Y, Tan Y, Shi J, Zhang M, Huang H. Risk and prognostic factors of transplantation-associated thrombotic microangiopathy in allogeneic haematopoietic stem cell transplantation: a nested case control study: Risk and prognostic factors of TA-TMA. Hematological Oncology 2017;35:821-7. [DOI: 10.1002/hon.2310] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
10 Thoreau B, von Tokarski F, Bauvois A, Bayer G, Barbet C, Cloarec S, Mérieau E, Lachot S, Garot D, Bernard L, Gyan E, Perrotin F, Pouplard C, Maillot F, Gatault P, Sautenet B, Rusch E, Frémeaux-Bacchi V, Vigneau C, Fakhouri F, Halimi JM. Infection in Patients with Suspected Thrombotic Microangiopathy Based on Clinical Presentation. Clin J Am Soc Nephrol 2021;16:1355-64. [PMID: 34497111 DOI: 10.2215/CJN.17511120] [Reference Citation Analysis]
11 Gabr JB, Bilal H, Mirchia K, Perl A. The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy. J Investig Med High Impact Case Rep 2020;8:2324709620947266. [PMID: 32757799 DOI: 10.1177/2324709620947266] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Menne J, Delmas Y, Fakhouri F, Kincaid JF, Licht C, Minetti EE, Mix C, Provôt F, Rondeau E, Sheerin NS, Wang J, Weekers LE, Greenbaum LA. Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study. Clin Kidney J 2019;12:196-205. [PMID: 30976396 DOI: 10.1093/ckj/sfy035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
13 Ramgopal A, Sridar S, Dalal J, Kalpatthi R. Thrombotic Microangiopathy: Multi-Institutional Review of Pediatric Patients Who Underwent HSCT. J Pers Med 2021;11:467. [PMID: 34070379 DOI: 10.3390/jpm11060467] [Reference Citation Analysis]
14 Java A. Peri- and Post-operative Evaluation and Management of Atypical Hemolytic Uremic Syndrome (aHUS) in Kidney Transplantation. Adv Chronic Kidney Dis 2020;27:128-37. [PMID: 32553245 DOI: 10.1053/j.ackd.2019.11.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Portoles J, Huerta A, Arjona E, Gavela E, Agüera M, Jiménez C, Cavero T, Marrero D, Rodríguez de Córdoba S, Diekmann F; Matrix Investigators . Characteristics, management and outcomes of atypical haemolytic uraemic syndrome in kidney transplant patients: a retrospective national study. Clin Kidney J 2021;14:1173-80. [PMID: 33841863 DOI: 10.1093/ckj/sfaa096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Bascuñana A, Mijaylova A, Vega A, Macías N, Verde E, Rodríguez-Ferrero ML, Delgado A, Carbayo J, Goicoechea M. Thrombotic Microangiopathy in a Kidney Transplant Patient With COVID-19. Kidney Med 2021;3:124-7. [PMID: 33319192 DOI: 10.1016/j.xkme.2020.09.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Karpman D, Loos S, Tati R, Arvidsson I. Haemolytic uraemic syndrome. J Intern Med 2017;281:123-48. [DOI: 10.1111/joim.12546] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 12.0] [Reference Citation Analysis]
18 Román E, Mendizábal S, Jarque I, de la Rubia J, Sempere A, Morales E, Praga M, Ávila A, Górriz JL. Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option. Nefrología (English Edition) 2017;37:478-91. [DOI: 10.1016/j.nefroe.2017.08.001] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
19 Lee H, Kang E, Kang HG, Kim YH, Kim JS, Kim HJ, Moon KC, Ban TH, Oh SW, Jo SK, Cho H, Choi BS, Hong J, Cheong HI, Oh D. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med. 2020;35:25-40. [PMID: 31935318 DOI: 10.3904/kjim.2019.388] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
20 Magnani HN. Rationale for the Role of Heparin and Related GAG Antithrombotics in COVID-19 Infection. Clin Appl Thromb Hemost 2021;27:1076029620977702. [PMID: 33539214 DOI: 10.1177/1076029620977702] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
21 Román E, Mendizábal S, Jarque I, de la Rubia J, Sempere A, Morales E, Praga M, Ávila A, Górriz JL. Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option. Nefrologia 2017;37:478-91. [PMID: 28946961 DOI: 10.1016/j.nefro.2017.01.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]